Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATAPEMBRO study of pembrolizumab combined with ataluren in metastatic mismatch repair-deficient or proficient colorectal cancer and mismatch repair-deficient endometrial carcinoma
NL-OMON59503Phase 2Completed
- Sponsor
- Amsterdam University Medical Center
- Start
- Sep 2019
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of pembrolizumab and ataluren in colorectal adenocarcinoma and endometrial cancer (EC) (3 arms), sponsored by Amsterdam University Medical Center. Started Sep 2019; status: completed.
02
Drugs
pembrolizumabataluren
03
Conditions
colorectal adenocarcinomaendometrial cancer (EC)
Beyond the preview
Go deeper on NL-OMON59503.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59503.